[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lund University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":337},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,80,105,139,163,194,225,252,275,304],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100621635","virtual-planning-of-total-temporomandibular-joint-replacement-100621635",false,"NCT07373184","Virtual Planning of Total Temporomandibular Joint Replacement","Three-dimensional Virtual Planning of Total Temporomandibular Joint Replacement Using Standardized Prosthesis.","Inclusion Criteria:\n\n* Patients with severe pathology in the temporomandibular joint.\n* Previously treated with TMJ prosthesis at the department of Oral and Maxillofacial Surgery, Skåne University Hospital, Lund, Sweden.\n* Treatments performed during year 2010 to 2025.\n\nExclusion Criteria:\n\n\\- Patients with additional surgical treatment of the TMJ after total TMJ replacement.","ALL",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","A total TMJ replacement surgery is currently planned based on the X-ray appearance of the facial X-ray. It is now possible to use either an individually designed TMJ prosthesis or a prosthesis with a standard appearance. It is a significantly higher cost for treatment with an individually manufactured prosthesis, but it also provides the opportunity for virtual planning of the positioning of the jaws and prosthesis.\n\nBy using a planning program with treatment simulation through the use of our own virtual models for standard prostheses, virtual planning of jaw and prosthesis positioning is possible even with a standardized temporomandibular joint prosthesis. In this way, the advantages of virtual planning are partly brought to the patients at a much lower price.\n\nThis project aims to virtually plan treatment for patients with standardized temporomandibular joint prosthesis. Patients eligible for this study are included retrospectively (have already been treated). Their X-rays will be used for treatment planning and for comparison with the treatment outcome of previous TMJ treatment.\n\nThe study will analyze the possibilities of the standardized prostheses to provide the same positions, temporomandibular joint replacements and movements of the jaw as an individual temporomandibular joint prosthesis has. This is done by measuring the planned positions of standardized temporomandibular joint prostheses compared to the treatment outcome shown by previous postoperative X-ray examinations.\n\nThe study aims to clarify the possibilities of a simpler and less expensive technology, standardized temporomandibular joint prostheses, to achieve the same good treatment outcome as a more costly technology. This with the same possibilities for treatment planning and use that the existing, more expensive technology, individual temporomandibular joint prostheses, has today.",[23,24],"Temporomandibular Disorders (TMD)","Temporomandibular Joint Ankylosis",[26,27,28,29,30],"temporomandibular joint","temporomandibular disorder","ankylosis","joint prosthesis","total joint replacement","RECRUITING","2026-02-04",{"date":34,"type":35},"2026-02-05","ACTUAL",{"date":37,"type":35},"2026-02-01",{"date":39,"type":19},"2027-12-31",{"name":41,"class":42},"Lund University Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100428426","personalized-radiotherapy-for-biochemical-recurrence-of-prostate-cancer-after-prostatectomy-100428426","NCT04858880","Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy.","Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy: a Randomized Phase III Study.","PROPER2","Inclusion Criteria:\n\n* Life expectancy \\> 10 years\n* Age ≥18 years.\n* World Health Organization (WHO) performance status 0-1.\n* Estimated life expectancy \\>10 years.\n* Histological evidence of prostate cancer in the prostatectomy specimen\n* Primary tumor, regional nodes, metastasis (TNM): any primary tumor (pT), pathologically node-negative (pN0), M0.\n* Biochemical Recurrence (BCR) after prostatectomy, with 0.15 ≤ PSA \\\u003C0.70 ng\u002Fml.\n* Patients must be able to comply with the protocol.\n* Signed informed consent.\n* Adequate laboratory findings (Haemoglobin (Hb) \\>90g\u002FL, absolute neutrophil count \\>1.0x109\u002FL, platelets \\>75x109\u002Fl, bilirubin \\\u003C1.5x upper limit of normal (ULN), alanine aminotransferase (ALAT) \\\u003C5x ULN and creatinine \\\u003C1.5 ULN).\n\nExclusion Criteria:\n\n* Metastases (regional lymph nodes or distant)\\* diagnosed with imaging.\n* Prior or ongoing hormonal therapy (antiandrogens or gonadotropin releasing hormone).\n* Prior radiotherapy to the pelvis.\n* Prior malignancy other than prostate cancer and basalioma in the past five years.\n* Clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) class III-IV congestive heart failure.\n* Severe pulmonary disease.\n* Any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial.","MALE","18 Years",{"count":55,"type":19},374,"INTERVENTIONAL",[58],"NA","A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA \\\u003C0.70 ng\u002Fml) after prostatectomy.",[61],"Prostate Cancer",[63,64,65,66,67,68,69,70],"Prostate cancer","Prostate-Specific Antigen PSA","PSA","Radiation","Lymph node radiation","Prostate cancer recurrence","Randomized trial","Prostatic Neoplasms","2025-09-10",{"date":73,"type":35},"2025-09-16",{"date":75,"type":35},"2021-04-09",{"date":77,"type":19},"2030-04",{"name":41,"class":42},3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":20,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100344001","sweden-cancerome-analysis-network---breast-recurrence-scan-b-rec-100344001","NCT03758976","Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)","SCAN-B-rec: Infrastructure, Technology Platform and Clinical Research Development to Profile and Monitor Metastatic Breast Cancer","Inclusion Criteria:\n\n1. Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease.\n2. Age \\> 18 years.\n3. Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2.\n4. ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET).\n5. Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion.\n6. Signed informed consent according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\nUntreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.",{"count":88,"type":19},2000,"10 Years","Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure.\n\nThe main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response\u002Fresistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.",[92],"Metastatic Breast Cancer",[94,95,96,97],"Metastatic breast cancer","Molecular profiling","Circulating tumor DNA","Circulating tumor cells",{"date":73,"type":35},{"date":100,"type":35},"2019-01-21",{"date":102,"type":19},"2030-12-01",{"name":41,"class":42},2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":56,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100469038","phase-3-systemic-targeted-adaptive-radiotherapy-of-neuroendocrine-tumors-100469038","NCT05387603","Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An Open-label, Multicenter, Randomized Phase III Trial Comparing Safety and Efficacy of Personalized Versus Non-personalized Radionuclide Therapy With 177Lu (Lutetium)-DOTATOC.","START-NET","Inclusion Criteria:\n\n* Age ≥18 years\n* Written informed consent\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n* Presence of histologically confirmed, advanced, well-differentiated, inoperable neuroendocrine tumors (NET) of any primary tumor origin and any grade, except for pheochromocytoma and paraganglioma.\n* Somatostatine receptor (SSTR)-expression in tumor lesions \\> basal liver uptake on 68Ga-DOTA-PET\n* Radiologically progressive disease within the last 1-24 months according to common clinical criteria and confirmed by the institutional multidisciplinary conference for the treatment of NETs. The CT\u002FMRI that shows tumor progression compared to screening\u002Fbaseline must have been performed 1-24 months earlier.\n* All previous anti-tumor treatment except SSA must be terminated at least 4 weeks before start of treatment within the trial.\n* Measurable disease according to RECIST v 1.1\n* Given the available, approved anti-tumor treatments and the specific characteristics of the patient and the tumor, the investigator judges peptide receptor radionuclide therapy (PRRT) to be the treatment of choice\n* GFR \\> 50 ml\u002Fmin\u002F1.73 m2 as determined by iohexol- or 51Cr-EDTA clearance, calculated according to a combination of LMR18 and CAPA formulas, or equally accurate method\n* Hemoglobin \\> 90 g\u002FL, platelets \\>100 x109\u002FL, leukocytes \\> 3.0x109\u002FL, neutrophils \\> 1.5 x109\u002FL, aspartate transaminase (ASAT)\u002Falanine aminotransferase (ALAT) \\\u003C 3 x ULN, bilirubin \\\u003C 2 x upper limit of normal (ULN), albumin \\> 25 g\u002FL\n* For women of child-bearing potential, highly effective contraception should be used from the time of inclusion up to at least six months after the end of treatment (EOT) visit.\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Previous treatment with PRRT\n* Concomitant systemic anti-tumor therapy other than somatostatin analogue (SSA)\n* Contraindications for treatment with capecitabine according to the approved label.\n* Discordance between CT\u002FMRI\u002F18F-FDG-PET and 68Ga-DOTA-PET, with evidence of tumor lesions without uptake on 68Ga-DOTATOC.\n* Any other serious, uncontrolled medical or psychiatric condition that, in the opinion of the investigator, precludes the patient from participation in the trial\n* Unwillingness, or inability, to participate in any part of the trial procedures or treatments.",{"count":114,"type":19},300,[116],"PHASE3","There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.",[119],"Neuroendocrine Tumors",[121,122,123,124,125,126,127,128,129,130],"Neuroendocrine tumors","Radionuclide therapy","Personalized radionuclide therapy","177Lu-DOTATOC","Capecitabine","Dosimetry-based radionuclide therapy","Somatostatin receptor","Lutetium","Beta- and gamma-emitting radionuclide","Translational research","2025-09-03",{"date":71,"type":35},{"date":134,"type":35},"2022-11-01",{"date":136,"type":19},"2026-10-01",{"name":41,"class":42},4,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":56,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":138},"100546043","phase-2-a-phase-2-open-label-study-of-pemigatinib-and-retifanlimab-in-advanced-dedifferentiated-liposarcoma-pereli-100546043","NCT06389799","A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)","A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma","PERELI","Inclusion Criteria:\n\nParticipants will be eligible for the study if all of the following criteria are met:\n\n1. Be 18 years of age or above, on day of signing informed consent.\n2. Must be willing and able to provide written informed consent. Written informed consent must be signed and dated before the start of specific protocol procedures.\n3. Must be willing and able to conform to and comply with all protocol requirements, including, all scheduled visits, protocol procedures, and the ability to swallow oral tablets.\n4. Histologically confirmed DDLPS\\*. Written pathology report indicating the diagnosis of DDLPS with positive MDM2 immunohistochemistry or MDM2 amplification as demonstrated by fluorescence in situ hybridization, polymerase chain reaction (PCR) or sequencing-based methods must be available.\n5. Have the presence of at least 1 measurable lesion by CT per RECIST v1.1 that is considered non amenable to surgery or other curative treatments or procedures. Tumor lesions located in a previously irradiated area or in an area subjected to other loco-regional therapy are considered measurable if progression has been demonstrated in the lesion.\n6. Disease relapse or radiological progression, as determined by the Investigator, within the last 6 months after at least one line of systemic treatment.\n\n   a. Patients considered to be medically unfit for chemotherapy, as assessed by the sarcoma centre in charge of the patient's treatment, can be considered for the trial after discussion with the trial steering committee.\n7. Be willing to provide tissue by core or excisional biopsy of a tumor lesion at the time points specified in the Trial Flow Chart. Archival tumor tissue can be used instead of pre-treatment biopsy. Biopsy will only be performed if the risk of complication is considered acceptable for the patient.\n8. Have a performance status of 0-2 on the ECOG Performance Scale.\n9. Patient must have adequate organ function as indicated by laboratory values obtained within 14 days of receiving the first dose of study drug (see study protocol)\n10. Female patients of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n11. Female patients of childbearing potential must be willing to use a highly effective method of contraception, for the course of the study through 180 days after the last dose of study medication. Please refer to Section 5.3 for list of highly effective contraception.\n12. Male patients must agree to use an highly effective method of contraception starting with the first dose of study therapy through 180 days after the last dose of study therapy.\n\nExclusion Criteria:\n\n1. Patient has received anticancer therapy within 28 days of the first administration of study treatment, with the exception of localized radiotherapy given to a lesion not considered for RECIST measurements.\n2. Toxicity of prior therapy that has not recovered to ≤ Grade 1 with the exception of\n\n   1. Alopecia\n   2. Peripheral neuropathy\n   3. Anemia not requiring transfusional support\n   4. Other toxicities may be considered acceptable (not an exclusion criteria) upon discussion with the Sponsor.\n3. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n4. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n5. Hypersensitivity to pemigatinib or retifanlimab or any of its excipients. 6. Patients with a prior or concurrent malignant disease whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible. Exceptions include, but are not limited to, patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor), patients with a history of prostate cancer, requiring continued support with luteinizing hormone- releasing hormone (LHRH) agonists, with or without androgens, basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n\n7\\. Has known active central nervous system (CNS) metastases and\u002For sarcomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include sarcomatous meningitis which is excluded regardless of clinical stability.\n\n8\\. Has an active autoimmune disease requiring systemic immunosuppression with corticosteroids (\\> 10 mg\u002Fday of prednisone or equivalent) or immunosuppressive drugs within 14 days before the first dose of study treatment.\n\n9\\. Receiving chronic systemic corticosteroids (\\> 10 mg\u002Fday of prednisone or equivalent):\n\nNotes:\n\n1. Physiologic corticosteroid replacement therapy at doses \\> 10 mg daily of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted.\n2. Participants with a condition that requires intermittent use bronchodilators, inhaled steroids, or local steroid injections may be admitted (eg, asthma or chronic obstructive pulmonary disease exacerbation).\n3. Participants using topical, ocular, intra-articular, or intranasal steroids (with minimal systemic absorption) may be admitted.\n4. Brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or study treatment-related standard premedication is permitted.\n\n   10\\. Has a history of organ transplant, including allogeneic stem cell transplantation.\n\n   11\\. Has an active infection requiring systemic antibiotics or antifungal or antiviral treatment within 7 days before first dose of study treatment.\n\n   12\\. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.\n\n   13\\. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\n   14\\. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 180 days after the last dose of trial treatment.\n\n   15\\. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n\n   16\\. Has received prior therapy with a selective FGFR inhibitor. 17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies).\n\n   18\\. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n\n   19\\. Has received a live vaccine within 30 days of planned start of study therapy.\n\na. Note: COVID-19 vaccines are allowed. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.\n\n20\\. Has a history of calcium or phosphate homeostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues such as the skin, kidney tendon, or vessel due to injury, disease, or aging in the absence of systemic mineral imbalance).\n\n21\\. Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.\n\n22\\. Has current evidence of clinically significant corneal (including, but not limited to, bullous\u002Fband keratopathy, corneal abrasion, inflammation\u002Fulceration, keratoconjunctivitis) or retinal disorder (including, but not limited to, macular\u002Fretinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination 23. Has a history of hypovitaminosis D currently requiring supraphysiologic doses (eg, 50,000 UI\u002Fweekly) to replenish the deficiency. Vitamin D supplements are allowed.","100 Years",{"count":149,"type":19},33,[151],"PHASE2","Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options.\n\nImmunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy.\n\nThe study aims to investigate whether the combination of an FGFR inhibitor, pemigatinib, with a PD-1 inhibitor, retifanlimab can provide a tumor-slowing effect in patients with advanced DDLPS who have progressed on first-line treatment.",[154],"Dedifferentiated Liposarcoma","2025-08-22",{"date":157,"type":35},"2025-08-28",{"date":159,"type":35},"2024-06-20",{"date":161,"type":19},"2028-12-31",{"name":41,"class":42},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":56,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":138},"100445113","aerobic-versus-leisure-group-for-adolescents-with-depression-100445113","NCT05076214","Aerobic Versus Leisure Group for Adolescents With Depression","A Randomised Multicentre Study Comparing Vigorous Group Aerobic Exercise vs. Group Leisure Activities for Mild to Moderate Depression in Adolescents","Inclusion Criteria:\n\n* DSM-5 mild to moderate depression\n* who have received evaluation and basic psychosocial interventions for 4-8 weeks (minimum three visits) without response, i.e. not achieved improvement by at least 50 % as assessed from clinical records\n\nExclusion Criteria:\n\n* Severe depression\n* Eating disorder\n* High risk for suicide\n* Intellectual disability\n* Actual physical activity the last four weeks meeting the level for sustained health by American College of Sports Medicine, i.e. at least 150 min per week of moderate intensity or 75 min per week of high intensity38\n* Adjustment of antidepressant medication within the last four weeks or stimulants the last two weeks\n* Chronic somatic illness precluding exercise\n* In need of interpreter\n* Social circumstances interfering with a regular exercise schedule\n* Concomitant psychotherapy","13 Years","17 Years",{"count":173,"type":19},122,[58],"The aim is to evaluate aerobic group exercise versus leisure group activities in adolescents with mild to moderate depression.\n\nPrimary outcome is Children's Depression Rating Scale - Revised (CDRS-R). Secondary outcomes are Clinical Global Impressions - Severity and Improvement scales (CGI), self-reported Quick Inventory of Depression Symptomatology (QIDS- A17-SR), the self-reported Outcome Rating Scale (ORS), clinician rated Children Global Assessment Scale (C-GAS), aerobic capacity (VO2max), muscular strength, body, Body Mass Index (BMI), presence or activity of selected biological markers of neuroprotection and neuroinflammation in blood samples and a cost evaluation rated by parents with Trimbos\u002FiMTA questionnaire for Costs associated with Psychiatric Illness - Child version (Tic-P) and the Child Health Utility (CHU9D) to facilitate estimation of Quality Adjusted Life Years. Further objectives are qualitative interviews to explore adolescents' experiences of the intervention as well as how their health and lifestyle are influenced and a validation of QIDS- A17-C and QIDS- A17-SR versus CDRS-R will be performed.",[177],"Depressive Disorder, Major",[179,180,181,182,183,184,185],"adolescent","depression","exercise intervention","leisure intervention","biomarker","cost evaluation","qualitative","2025-03-21",{"date":188,"type":35},"2025-03-26",{"date":190,"type":35},"2022-02-28",{"date":192,"type":19},"2026-03-10",{"name":41,"class":42},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":16,"minAge":53,"maxAge":147,"enrollmentInfo":202,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":43},"100431902","predictive-and-prognostic-biomarkers-in-patients-with-mycosis-fungoides-and-szary-syndrome-100431902","NCT04904146","Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.","BIO-MUSE","Inclusion Criteria:\n\n* Age 18-100 years\n* Histologically confirmed (according to the World Health Organization (WHO)\u002FEORTC classification) MF\u002FSS stages I-IV\n* WHO performance status 0 -3\n* Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.\n* Written informed consent according to International Conference on Harmonization (ICH)\u002F(Good Clinical Practice (GCP), and Swedish regulations\n* No minimum or maximum required routine laboratory data\n\nExclusion Criteria:\n\nNot applicable. No exclusion criteria are specified.",true,{"count":203,"type":19},120,"A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.",[206,207],"Mycosis Fungoides","Sezary Syndrome",[209,210,211,130,212,213,214,215,216],"Skin lymphoma","Mycosis fungoides","Sezary syndrome","Biomarkers","Treatment prediction","Lymphoma microenvironment","Skin neoplasms","Treatment","2025-03-05",{"date":219,"type":35},"2025-03-10",{"date":221,"type":35},"2021-04-02",{"date":223,"type":19},"2027-04",{"name":41,"class":42},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":147,"enrollmentInfo":233,"targetDuration":4,"studyType":56,"phases":235,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":5},"100535220","phase-3-a-multicentre-phase-iii-study-of-risk-based-treatment-intensification-with-hyperfractionated-radiotherapy-in-head-and-neck-cancer-patients-100535220","NCT06248996","a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients","ARTSCAN VI Protocol Version 1, 2023-07-03 ARTSCAN VI - a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients","ARTSCAN VI","Inclusion Criteria:\n\n1. The patient must be at least 18 years old.\n2. Histologically or cytologically confirmed, previously untreated, HNSCC of the oropharynx, hypopharynx, larynx or oral cavity without distant metastases and aimed for treatment with radiotherapy (with or without concomitant chemotherapy) with curative intent.\n3. The primary tumour must fulfil the following high-risk criteria:\n\n   1. For p16+ oropharyngeal cancer: Radiographic measurement of threeorthogonal diameters must render a tumour estimate of ≥30 cc.\n   2. For all other subsites and for p16- oropharyngeal cancer: Radiographic measurement of three orthogonal diameters must render a tumour estimate of ≥20 cc.\n4. The treatment may be followed but not preceded by surgery, either as a salvage procedure or a neck dissection. An excision of a lymph node or tonsillectomy for diagnostic purposes, does not exclude the patient from participation.\n5. WHO\u002FECOG performance status 0-2\n6. The patient must be able to understand the information about the treatment and give a written informed consent to participate in the trial.\n\nExclusion Criteria:\n\n1. Previous radiotherapy in the head and neck region.\n2. Concomitant or previous malignancies, except uncomplicated basal cell carcinoma, early (T1-2 N0) squamous cell carcinoma of the skin with follow-up time of at least one year for squamous cell carcinomas, and except other cancer with a disease-free follow-up of at least three years\n3. Two or more synchronous primary HNSCC at time of diagnosis\n4. Nasopharyngeal cancer\n5. Sinonasal cancer\n6. Co-existing disease prejudicing survival (expected survival \\\u003C three years).\n7. Pregnancy or lactation\n8. Psychiatric or addictive disorders or other medical conditions which in the view of the investigator might impair patient compliance",{"count":234,"type":19},308,[116],"There is an unmet need to personalise treatment for patients with head and neck squamous cell carcinoma (HNSCC) and to improve treatment results for patients with advanced disease. In this phase III study, HNSCC patients with prognostic factors indicating increased risk of treatment failure that are aimed for curative treatment with radiotherapy (RT) will be randomised between standard treatment (conventionally fractionated RT with final RT dose 68.0 Gy) and hyperfractionated RT (HFX-RT) with final RT dose 83.0 Gy.\n\nIn order to find better prognostic and predictive tools the study also includes exploratory and translational analyses including evaluation of grade of hypoxia with Magnetic Resonance Imaging (MRI) and gene profiling by RNA-sequencing, tumour immune profiling, comparisons of global gene expression, gene aberrations and protein expression, and texture analyses of CT, FDG-PET and MRI images used during RT preparation and during patient follow-up. Patients with tumours with lower risk of recurrence, not eligible for randomisation in the study, can still participate in the translational parts of the study not investigating response to altered fractionation.",[238],"Head and Neck Squamous Cell Carcinoma",[240,241,242,243],"Head and neck squamous cell carcinoma","radiotherapy","HNSCC","Hyperfractionated radiotherapy","2024-09-12",{"date":246,"type":35},"2024-09-19",{"date":248,"type":35},"2024-03-04",{"date":250,"type":19},"2033-03-04",{"name":41,"class":42},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":56,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":43},"100479743","cytokine-filtration-in-lung-transplantation-a-swedish-national-study-glusorb-100479743","NCT05526950","Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)","Cytokine Filtration in Lung Transplantation - a Randomised, Controlled, Multicentre Clinical Trial (GLUSorb)","Inclusion Criteria:\n\n• Eligibility to undergo double lung transplantation at either trial site\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Previous organ transplantation\n3. Presence of any conditions at the time of surgery that require immunosuppressive therapy. Immunosuppressive therapy is defined as:\n\n   1. Cyclosporine, Tacrolimus, Everolimus, or Sirolimus, minimum 1 month of treatment prior to transplantation and active treatment at the time of transplantation.\n   2. Any form of antibody-based treatment that is known for having an immunomodulatory effect taken up to 1 week before transplantation.\n4. Non-consent","80 Years",{"count":261,"type":19},116,[58],"Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) which is the leading cause of late mortality. PGD develops within the first 72 hours after LTx. The development of CLAD increases quickly with cumulative incidence of 40-80 % within the first 3-5 years. There is a general lack of efficient treatments for PGD and CLAD. Prevention of PGD is therefore of crucial importance and has a direct impact on survival.\n\nThe present study is a randomized controlled study which aims to compare patients undergoing LTx with and without the utilization of cytokine adsorption.",[265,266],"Lung Transplant Failure","Lung Transplant; Complications","2023-09-14",{"date":269,"type":35},"2023-09-18",{"date":271,"type":35},"2023-09-07",{"date":273,"type":19},"2029-12-31",{"name":41,"class":42},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":282,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":43},"100468082","exhaled-breath-particles-in-lung-transplantation-100468082","NCT05375149","Exhaled Breath Particles in Lung Transplantation","Exhaled Breath Particles as a Clinical Indicator for Acute and Chronic Rejection After Lung Transplantation","Inclusion Criteria:\n\n* Patients who have undergone LTx at Skåne University Hospital, SUS Lund\n\nExclusion Criteria:\n\n* None","16 Years","75 Years",{"count":285,"type":19},150,"Lung transplantation (LTx) is the only effective treatment for patients with end stage lung disease. Of the major organs transplanted, survival following LTx is the lowest with a mean of 5 years. Despite improvements, primary graft dysfunction (PGD) remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) that remains the leading cause of late mortality. Earlier detection of rejection after LTx is of substantial importance as it would improve the possibilities of treatment and could increase survival.\n\nThe investigators have shown in previous work that exhaled breath particles (EBP) reflect the composition of respiratory tract lining fluid (RTLF). EBP and particle flow rate (PFR) can be used as non-invasive methods for early detection and monitoring of airway diseases such as acute respiratory distress syndrome (ARDS). It has also been shown that the particle flow prolife after lung transplantation differs between patients who develop PGD and those who do not and that the composition of EBP differs between patients with and without bronchiolitis obliterans syndrome (BOS), an obstructive form of CLAD.\n\nSamples of EBP and measurements of PFR will be collected from lung transplanted patients. Membranes with EBP will be saved for molecular analysis. The investigators aim to identify potential particle flow patterns and biomarkers for earlier detection of rejection after lung transplantation.",[288,289,290],"Lung Transplant Rejection","Primary Graft Dysfunction","Chronic Rejection of Lung Transplant",[292,293,294,289,295],"Exhaled Breath Particles","PExA","Lung transplantation","Chronic Lug Allograft Dysfunction","2022-05-10",{"date":298,"type":35},"2022-05-16",{"date":300,"type":35},"2018-09-18",{"date":302,"type":19},"2026-09",{"name":41,"class":42},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":56,"phases":313,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":336},"100349378","photon-therapy-versus-proton-therapy-in-early-tonsil-cancer-100349378","NCT03829033","Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.","ARTSCAN V","Inclusion Criteria:\n\n1. The patient must be at least 18 years old.\n2. Histologically or cytologically confirmed, previously untreated squamous cell carcinoma of the tonsil T1-2 (p16-positive or p16-negative) N0-1 M0 (p16-positive)\u002FN0-N2b M0 (p16-negative) according to AJCC 8th edition, aimed for unimodal and ipsilateral treatment with radiotherapy with curative intent. The treatment may be followed but not preceded by surgery, which would be as a salvage procedure and not part of the planned treatment. An excision of a lymph node, or a tonsillectomy for diagnostic purposes does not exclude the patient from participation.\n3. World Health Organisation\u002FEastern Cooperative Oncology Group (WHO\u002FECOG) performance status 0-1.\n4. The patient must be able to understand the information about the treatment and give a written informed consent.\n\nExclusion Criteria:\n\n1. Patients judged to benefit from bilateral radiotherapy or concomitant chemotherapy\n2. Concomitant or previous malignancies. Exceptions are adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix uteri with a follow-up time of at least 3 years, or other previous malignancy with a disease-free interval of at least 5 years.\n3. Two or more synchronous primary cancers in the head and neck region at time of diagnosis\n4. Previous surgery or radiotherapy in the head and neck region that may affect the study result, as judged by the investigator\n5. Co-existing disease prejudicing survival (expected survival should be \\>2 years).\n6. Psychiatric or addictive disorders or other medical conditions which in the view of the investigator might impair patient compliance\n7. When dental fillings with amalgam or metal are present close to the tumour area it must be considered if this may affect radiotherapy before inclusion.",{"count":312,"type":19},100,[58],"In this trial, patients with early squamous cell carcinoma of the tonsil with clinical stage T1-2 (p16-positive or p16-negative) N0-1 (p16-positive)\u002FN0-N2b (p16-negative) according to American Joint Committee on Cancer (AJCC) 8th edition, aimed for unimodal and ipsilateral treatment with radiotherapy with curative intent will be included. The patients will be randomized to in a 1:1 ratio to receive radiotherapy with either photons (conventional radiotherapy) versus radiotherapy with protons.",[316],"Tonsil Cancer",[316,318,319,320,321,322,323,324,325,326,327],"Early Tonsil Cancer","Radiotherapy","Photons","Protons","Acute Side Effects","Late Side Effects","Locoregional Control","Disease Free Survival","Quality of Life","Health Economic","2021-08-31",{"date":330,"type":35},"2021-09-01",{"date":332,"type":35},"2019-01-22",{"date":334,"type":19},"2028-01",{"name":41,"class":42},12,""]